QED Therapeutics
Rocio Reategui MD is an experienced medical professional specializing in oncology, currently serving as a Medical Monitor and Clinical Development Consultant at QED Therapeutics since March 2022 and as a Medical Director at Medical Monitoring Solutions since July 2020. Previously, Rocio held various positions in notable organizations, including Medical Advisor roles at Roche and Pfizer, and served as a Medical Oncologist and Principal Investigator at Instituto Oncologico de Lima and Edgardo Rebagliati Martins National Hospital. Rocio's educational background includes a Master in Molecular Oncology from the Spanish National Cancer Research Center and a degree in Medical Oncology and Medical Doctor (MD) from Federico Villarreal National University.
This person is not in any offices
QED Therapeutics
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.